Cryo-Cell Featured in Article by CBS Phoenix, AZ Affiliate KPHO on Benefits of Menstrual Blood Banking
March 15, 2011
Oldsmar, FL – March 15, 2011 – Cryo-Cell International, Inc. (OTCQB: CCEL) (the “Company”), one of the world’s largest and most established family cord blood banks and global industry leader in innovative stem cell solutions, announced that the Company was featured in an article by CBS Phoenix, AZ affiliate KPHO titled, “Banking Menstrual Blood Could Save Lives.”
“We are very excited about the continuing progress of Célle technology and we look forward to its prospective adaptation as increasing numbers of people recognize the possible benefits of menstrual blood banking,” said Mercedes Walton, Chairman & CEO of Cryo-Cell International. “The Company’s revolutionary stem cell technology could possibly open the doors to a broad range of potential therapies that may radically transform the way that patients are treated in the future.”
About Cryo-Cell International, Inc.
Based in Oldsmar, Florida, with over 230,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2008 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. In November 2007, the Company launched Célle(SM) (pronounced “C-L”), the world’s first-ever commercial service allowing women to cryopreserve their own menstrual stem cells. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.
About Cryo-Cell’s Menstrual Stem Cell Service
Cryo-Cell’s Menstrual Stem Cell service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.cryo-cell.com.
Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s Célle technology license agreements and U-Cord license agreements and their ability to provide the Company with royalty fees, the ability of Cryology RTS to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.